Actelion Ltd (ATLN.VX)

ATLN.VX on Virt-X Level 1

61.50CHF
31 Jul 2013
Price Change (% chg)

CHF0.50 (+0.82%)
Prev Close
CHF61.00
Open
CHF60.75
Day's High
CHF61.90
Day's Low
CHF60.75
Volume
479,923
Avg. Vol
418,965
52-wk High
CHF62.30
52-wk Low
CHF42.85

ATLN.VX

Chart for ATLN.VX

About

Actelion Ltd is a Switzerland-based biopharmaceutical holding company that focuses on the discovery, development and commercialization of small molecule drugs. The Company has four approved drugs on the market: Tracleer, an oral dual endothelin receptor antagonist; Veletri, a prostanoid vasodilator; Ventavis, an inhaled... (more)

Overall

Beta: 0.59
Market Cap (Mil.): CHF7,396.97
Shares Outstanding (Mil.): 120.28
Dividend: 1.00
Yield (%): 1.63

Financials

  ATLN.VX Industry Sector
P/E (TTM): 21.75 47.13 37.76
EPS (TTM): 2.83 -- --
ROI: 16.61 -2.58 18.76
ROE: 22.22 -2.66 19.59
Search Stocks

UPDATE 1-Actelion buys U.S.-based specialty drugmaker Ceptaris

* Ceptaris drug Valchlor set to be addressed by FDA in Aug

31 Jul 2013

Actelion buys U.S.-based firm with cancer drug in development

ZURICH - Actelion said it will acquire Ceptaris, a privately held U.S.-based specialty pharmaceutical company developing a topical drug, Valchlor, to treat a form of cancer.

31 Jul 2013

Actelion raises profit forecast as cost cuts kick in

ZURICH - Actelion , the Swiss drugmaker which relies on sales of its treatment for a rare lung disease, raised its full-year profit forecast on Thursday on cost-savings and better-than-expected sales of its mainstay product.

18 Jul 2013

UPDATE 2-Actelion raises profit forecast as cost cuts kick in

* Shares rise 1 pct, outperform flat sector (Adds CFO comment, shares, details on ponesimod)

18 Jul 2013

BRIEF-Shares in Actelion up 2 pct after raises forecast

ZURICH, July 18 - Actelion Ltd : * Shares in Actelion rise 2 percent after raises profit growth forecast for

18 Jul 2013

Actelion CFO sees room for upside to 2014, 2015 guidance

ZURICH, July 18 - Actelion could upgrade its earnings guidance for 2014 and 2015 if sales of its new heart and lung drug are better than expected, the company's Chief Financial Officer said on Thursday.

18 Jul 2013

CORRECTED-Actelion raises full-year guidance

ZURICH, July 18 - Actelion, Europe's largest biotech company lifted its full-year guidance on Thursday and now expects to return to growth in 2013 boosted by strong sales of its mainstay product and benefits from its cost-savings programme.

18 Jul 2013

UPDATE 1-Actelion gets go-ahead to continue new drug trial

* Selexipag is new drug for pulmonary arterial hypertension

08 May 2013

Actelion gets go-ahead to continue new drug trial

ZURICH, May 8 - Actelion should continue a late-stage study into a new heart and lung drug, independent monitors have recommmended, with final results now expected by mid-2014, giving the biotech firm hope it has a further product in its pipeline.

08 May 2013

Actelion shareholders reject biotech firm's pay plans

BASEL - Actelion shareholders rejected a $5.6 million pay award for the biotechnology company's chief executive Jean-Paul Clozel on Thursday, making it the second Swiss company in as many weeks to have its pay plans voted down by investors.

18 Apr 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$483.00
Provider: ValuEngine, Inc.
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks